title: Adjuvant therapy in invasive thymoma: an audit of cases treated over an 8 year period.
abstract: Invasive thymomas comprise 0.1%-0.2% of all malignancies in India. This report is an audit of 11 cases (10 males and 1 female) at a mean age of 36.6 years (range 25-52 years) of invasive thymoma accrued over an eight year period treated by combined modality treatment. Nine of these presented with myaesthenia gravis. All patients underwent initial surgery (3 partial and 8 total resections) and postoperative radiotherapy. Two of the three partially resected patients received one course of chemotherapy prior to radiotherapy consisting of cyclophosphamide, vincristine, procarbazine and prednisolone. At a median follow up of 28 months (range 2-87) there have been no local relapses, one distant metastasis and one death due to uncontrolled myaesthenia. The treatment strategies with invasive thymomas would depend upon the extent of resection. Postoperative radiotherapy appears to be indicated in all cases, however the role of chemotherapy may be limited to those with partial resection.
authors.affiliation: Department of Radiotherapy, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Utter Pradesh, India.
authors.forename: S
authors.initials: S
authors.lastname: Agrawal
authors.forename: N R
authors.initials: NR
authors.lastname: Datta
authors.forename: S K
authors.initials: SK
authors.lastname: Mishra
authors.forename: S
authors.initials: S
authors.lastname: Kumar
authors.forename: V
authors.initials: V
authors.lastname: Tandon
authors.forename: S
authors.initials: S
authors.lastname: Ayyagari
authors.forename: A
authors.initials: A
authors.lastname: Agarwal
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002423:Cause of Death; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007194:India; D008297:Male; D008485:Medical Audit; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000209:etiology; D009361:Neoplasm Invasiveness; D011239:Prednisolone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D013934:Thymectomy; D013945:Thymoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D013953:Thymus Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D003037:Cobalt Radioisotopes; D019275:Radiopharmaceuticals; D011344:Procarbazine; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone